Home › Head and Neck Squamous Cell Carcinoma › NCT07741643

Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

Phase I Open-Label Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Age ≥ 18 years.
2. Subjects diagnosed with any T stage or N stage squamous cell carcinoma and any subsite within the head and neck that are scheduled to undergo surgical resection and neck dissection. Subjects with recurrent disease or a new primary will be allowed.
3. Have acceptable hematologic status, kidney function, and liver function including the following clinical results:

   * Hemoglobin ≥ 9 gm/dL
   * White blood cell count \> 3000/mm3
   * Platelet count ≥ 100,000/mm3
   * Serum creatinine ≤ 1.5 times upper reference range
   * Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment.
2. Evidence of QTcF prolongation on ECG within 30 days of pan800 administration (greater than 480 ms).
3. History of infusion reactions to monoclonal antibody therapies.
4. History of allergies to iodine.
5. Pregnant or breastfeeding.
6. Magnesium or phosphorus lower than the normal institutional values and the patient is symptomatic.
7. Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
8. Subjects with history or evidence of interstitial pneumonitis or pulmonary fibrosis.
9. Severe renal disease or anuria.

About the study

The goal of this clinical trial is to learn whether using two imaging agents-Panitumumab-IRDye800 (Pan800) and\[18F\]NOTA-ABY-030-is safe and feasible for helping surgeons identify tumors and cancer-containing lymph nodes during surgery in adults with head and neck squamous cell carcinoma (HNSCC) who are scheduled for tumor removal and neck dissection.

The main questions it aims to answer are:

* Is the combination of Pan800 and \[18F\]NOTA-ABY-030 safe and well tolerated in patients undergoing surgery for HNSCC? * How accurately can Pan800 and \[18F\]NOTA-ABY-030 detect tumor tissue and cancer-positive lymph nodes when compared with final pathology results?

This is a single-arm, open-label study, so there is no comparison group.

Study Related Steps:

* Receive an intravenous infusion of Pan800 1-2 days before surgery. * Receive an intravenous injection of\[18F\]NOTA-ABY-030 on the day of surgery.

What is being tested

• Panitumumab-IRDye800 (drug)
• [18F]NOTA-ABY-030 (drug)

Sponsor: Vanderbilt-Ingram Cancer Center · Participants: 30 · Started: Sep 15, 2026

Contact the study team

• Makenna Brown · Phone: 6154214370

Official record on ClinicalTrials.gov — NCT07741643

Locations in the U.S.

Conditions

• Head and Neck Squamous Cell Carcinoma
• Squamous Cell Carcinoma
• Head and Neck Cancer

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.